| Pharmaceutical active ingredients: |
| Fluticasone PropionateSalmeterol Xinafoate |
| Available forms, composition and doses of Maizar: |
| N / A |
| Maizar medical category: |
| Human:Antiasthmatic and COPD preparationsOrally inhaled preparationsSelective beta-2-adrenergic agonists |
| Indications and usages, anatomical therapeutic chemical and diseases classification codes: |
| R01AD08 - FluticasoneR03AK06 - Salmeterol and other drugs for obstructive airway diseasesR03BA05 - Fluticasone |
| Pharmaceutical companies: manufacturers, researchers, developers, local distributors and suppliers: |
| Vitoria Laboratorios |
| Trade name |
Active ingredients |
Pharmaceutical company |
|
Brisair | Fluticasone Propionate; Salmeterol Xinafoate | GlaxoSmithKline |
| Brisomax | Fluticasone Propionate; Salmeterol Xinafoate | Bial Laboratorios |
| Flutivent | Fluticasone Propionate; Salmeterol Xinafoate | Pablo Cassara Laboratorios |
| Fluxamol | Fluticasone Propionate; Salmeterol Xinafoate | Pablo Cassara Laboratorios |
| Inaladuo | Fluticasone Propionate; Salmeterol Xinafoate | Faes Farma |
| Plusvent | Fluticasone Propionate; Salmeterol Xinafoate | Almirall |
| Salmeflo | Fluticasone Propionate; Salmeterol Xinafoate | InnoGen Pharma Group |
| Seretaide | Fluticasone Propionate; Salmeterol Xinafoate | GlaxoSmithKline |
| Seretide | Fluticasone Propionate; Salmeterol Xinafoate | GlaxoSmithKline; Firma Chun Cheong; Zuellig Pharma |
| Seretide CFC-free | Fluticasone Propionate; Salmeterol Xinafoate | GlaxoSmithKline |